GlassScriptPhysician profile
Joanna Falcon
NPI 1689254039
$1,190.32
in general payments reported to CMS, 2019-2025
17 companies · $760 in 2025
The $760 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.40 · 2023: $163 · 2024: $251 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $211.94 | 2023-2025 | Tezspire, Farxiga, Airsupra |
| Novo Nordisk INC | $181.30 | 2023-2025 | Wegovy, Ozempic |
| Tandem Diabetes Care, INC. | $144.55 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Madrigal Pharmaceuticals | $98.53 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $87.91 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.36 | 2024-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $84.32 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $75.42 | 2021-2025 | |
| Abbvie INC. | $39.63 | 2023 | |
| Pfizer INC. | $30.86 | 2025 | |
| Averitas Pharma INC. | $27.69 | 2025 | Qutenza |
| Phadia US INC. | $26.58 | 2024 | Immunocap |
| Hologic Sales and Service, LLC | $24.10 | 2025 | Aptima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.86 | 2025 | Xifaxan |
| Gilead Sciences, INC. | $20.39 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.72 | 2023 | Tezspire |
| Smith+Nephew, INC. | $14.16 | 2025 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Falcon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.